Phase 2 trials reported mean systolic blood pressure reductions of approximately 46 mmHg in higher-dose groups, alongside a modest increase in heart rate consistent with the GLP-1 drug class
WADA status The 2026 WADA Prohibited List bans GHRH and its analogues, including tesamorelin, as well as growth-hormone secretagogues and ghrelin mimetics, including ipamorelin
Results suggested that female mice with impaired Kisspeptin systems exhibited dramatic increases in body weight and significantly impaired glucose tolerance levels
Zanin, M., Baviskar, P., Webster, R
While no reviews are currently found on Amazon, this may be due to the program being a prescription-based service, limiting its availability to a broader market
Rotating injection sites across the abdomen, lateral thighs, and upper arms in a systematic pattern (using each site no more than once every 46 weeks) prevents this entirely